GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Ending Cash Position

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Ending Cash Position : $6.82 Mil (As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Ending Cash Position?

CERo Therapeutics Holdings's Ending Cash Position for the quarter that ended in Dec. 2022 was $6.82 Mil.

CERo Therapeutics Holdings's quarterly Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2021 ($19.22 Mil) but then declined from Dec. 2021 ($19.22 Mil) to Dec. 2022 ($6.82 Mil).

CERo Therapeutics Holdings's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2021 ($19.22 Mil) but then declined from Dec. 2021 ($19.22 Mil) to Dec. 2022 ($6.82 Mil).


CERo Therapeutics Holdings Ending Cash Position Historical Data

The historical data trend for CERo Therapeutics Holdings's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Ending Cash Position Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Ending Cash Position
19.22 6.82

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Ending Cash Position 19.22 6.82

CERo Therapeutics Holdings Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

CERo Therapeutics Holdings's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=19.217+-12.397
=6.82

CERo Therapeutics Holdings's Ending Cash Position for the quarter that ended in Dec. 2022 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=19.217+-12.397
=6.82


CERo Therapeutics Holdings Ending Cash Position Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines